Participation in Lilly "TuneLab"
Boosting Candidate Discovery and Development Efficiency by Integrating Proprietary AI Platform

Aribio announced on June 5 that it will participate in Eli Lilly's AI drug discovery platform, "Lilly TuneLab."


Aribio company logo image. Aribio

Aribio company logo image. Aribio

View original image

Through this participation, Aribio plans to combine more than 10 years of accumulated neuroscience research data with Lilly's AI and machine learning models to enhance its capabilities in developing central nervous system (CNS) therapeutics, including treatments for Alzheimer's disease and Lewy body dementia.


Lilly TuneLab is a platform that supports the drug development process by utilizing Eli Lilly's accumulated research data and AI/machine learning models. It increases the predictive accuracy of candidate discovery and development processes based on data such as pharmacokinetics (PK), safety, preclinical research results, and molecular structure information.


Aribio will enhance its data-driven decision-making capabilities across its neuroscience pipeline by combining more than 10 years of accumulated neuroscience research data with the TuneLab AI models. In particular, the company plans to participate in improving the AI model's performance in a federated learning environment without transferring its proprietary data externally.


The company also aims to improve the efficiency of CNS pipeline development by linking its own AI-based drug discovery platform "ARIDD" with Lilly TuneLab. Aribio is currently developing multi-mechanism Alzheimer's disease therapeutic AR1001 and Lewy body dementia therapeutic AR1005, among others.



Jaejoon Jung, CEO of Aribio, stated, "Through this participation in TuneLab, we will strengthen our capabilities in developing therapeutics for neurodegenerative diseases by leveraging global-level AI and machine learning technologies. By combining our proprietary AI platform with a global collaboration network, we will accelerate the development of next-generation central nervous system (CNS) therapeutics."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing